Extract
It is with great pleasure that we introduce the new editorial team at the European Respiratory Journal (ERJ) as we begin our 5-year mandate at the helm of the flagship journal of the European Respiratory Society (ERS). When the Starship Enterprise started their 5-year mission in 1966 to explore strange new worlds and new civilisations, they promised to boldly go where no-one had gone before. Science is a voyage of discovery and as with previous ERJ editorial teams, the journal's mission is to explore new topics, identify exciting new avenues of investigation, discover new treatments, and ultimately improve the health of our patients through innovation and cutting-edge science. We can only get there by pushing the boundaries of respiratory science.
Abstract
The new European Respiratory Journal Chief Editor James Chalmers and Deputy Chief Editor Don Sin discuss the future direction of the journal and highlights from 2022 https://bit.ly/3vrJ9ex
Footnotes
Conflict of interest: J.D. Chalmers has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Grifols, Novartis, Insmed and Trudell, and received consultancy or speaker fees from Antabio, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Insmed, Janssen, Novartis, Pfizer, Trudell and Zambon. D.D. Sin has received a stipend for giving talks on COPD from AstraZeneca, GlaxoSmithKline and Boehringer Ingelheim.
- Received December 23, 2022.
- Accepted December 23, 2022.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org